Sort
17,288 grants matching “multiple sclerosis”
Comprehensive multimodal analysis of patients with neuroimmunological diseases
$1,426,974Bibiana Bielekova · National Institute Of Neurological Disorders And Stroke · ZIA · FY2018 · NS
Nuclear receptors: action, functions, and roles in disease
$1,424,077Anton M Jetten · National Institute Of Environmental Health Sciences · ZIA · FY2010 · ES
Cytokines and T Cell Development
$1,423,160Scott Durum · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
IMAGING EFFECTS OF NEUROTROPHIC FACTOR GENES ON BRAIN PLASTICITY AND REPAIR IN MULTIPLE SCLEROSIS
$1,422,000Trustees Of Dartmouth College · · FY2009 · Department of Defense
Development of a novel, regenerative therapy to reverse synapse loss in Alzheimer's Disease
$1,419,610Peter W Vanderklish · Spinogenix, Inc. · R44 · FY2023 · AG
Molecular Mechanisms of Fate Choice in Neural Stem Cells
$1,419,279Dana-Farber Cancer Institute · P01 · FY2004 · NS
Antigen Specific Therapy in CNS Autoimmune Diseases
$1,418,846Howard L Weiner · Brigham And Women'S Hospital · P01 · FY2006 · NS
Molecular Regulation of B-Cell Differentiation and Function
$1,416,380Herbert Morse · Niaid Extramural Activities · Z01 · FY2007 · AI
SWITCH Trial: Early Feasibility Study of Stentrode BCI for Augmentative Communication
$1,416,223Douglas J Weber · Carnegie-Mellon University · UH3 · FY2024 · NS
Neurovascular Interactions: Mechanisms, imaging, therapeutic potential
$1,415,966Katerina Akassoglou · J. David Gladstone Institutes · R35 · FY2023 · NS
Neurovascular Interactions: Mechanisms, imaging, therapeutic potential
$1,415,966Katerina Akassoglou · J. David Gladstone Institutes · R35 · FY2022 · NS
Neurovascular Interactions: Mechanisms, imaging, therapeutic potential
$1,415,966Katerina Akassoglou · J. David Gladstone Institutes · R35 · FY2021 · NS
Immunogenetic Determinants of Disease Risk in Neurological Disease
$1,414,582Jorge R. Oksenberg · University Of California, San Francisco · U19 · FY2019 · NS
Immunogenetic Determinants of Disease Risk in Neurological Disease
$1,413,302Jorge R. Oksenberg · University Of California, San Francisco · U19 · FY2015 · NS
NRF2: A NOVEL BIOMARKER OF DISEASE SEVERITY AND TARGET FOR THERAPEUTIC INTERVENTION IN MULTIPLE SCLEROSIS
$1,413,000Case Western Reserve University · · FY2012 · Department of Defense
From therapeutic mechanisms to unraveling the pathophysiology of MS
$1,402,526Bibiana Bielekova · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Comprehensive multimodal analysis of patients with neuroimmunological diseases
$1,402,526Bibiana Bielekova · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Medicinal Chemistry of Drugs Acting on Central and Peripheral Opioid Receptors
$1,402,491Kenner Rice · National Institute On Drug Abuse · ZIA · FY2011 · DA
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD
$1,402,110Samuel V Alworth · Acurastem, Inc. · R44 · FY2024 · AG
A Controlled Trial of CBT for MS Inflammation
$1,401,523Northern California Institute Res &Educ · R01 · FY2003 · HD
Sex, Sex Steroids & Neuroprotection
$1,401,119Patricia D. Hurn · Oregon Health & Science University · P01 · FY2006 · NS
SBIR Phase II: Real-Time Rehab to Improve Gait Symmetry in Amputees
$1,400,498Stacy Bamberg · Veristride, Inc. · · FY2013 · TIP
HIV-1 and host interactions at molecular level
$1,400,080Maureen Goodenow · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Molecular Mechanisms of Fate Choice in Neural Stem Cells
$1,398,357Charles Stiles · Dana-Farber Cancer Inst · P01 · FY2006 · NS
High-throughput Oligonucleotide Production System
$1,397,364Anastasia Khvorova · Univ Of Massachusetts Med Sch Worcester · S10 · FY2024 · OD